Efficacy and Safety of Oral Versus Intravenous Vitamin C in Hemodialysis Patients with Functional Iron Deficiency

F Espahbodi; Z Kashi; S Ala; N Hendoii

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Efficacy and Safety of Oral Versus Intravenous Vitamin C in Hemodialysis Patients with Functional Iron Deficiency

Author(s):

F Espahbodi

^1,*,

Z Kashi²,

S Ala²,

N Hendoii²

1Imam Khomeini Hospital, Mazandaran University of Medical Sciences, ftespahbodi@yahoo.com, I.R.Iran

2Imam Khomeini Hospital, Mazandaran University of Medical Sciences, I.R.Iran

International Journal of Endocrinology and Metabolism:Vol. 5, issue 3; 130-134

Article type:Research Article

Received:May 17, 2007

Accepted:Aug 12, 2007

How to Cite:F EspahbodiZ KashiS AlaN HendoiiEfficacy and Safety of Oral Versus Intravenous Vitamin C in Hemodialysis Patients with Functional Iron Deficiency.Int J Endocrinol Metab.5(3):130-134.

Abstract

Hemodialysis patients (HD) with functional iron deficiency (FID) often develop resistance to re-combinant human erythropoietin (rHuEpo). Re-cent studies suggest that intravenous ascorbic acid (IVAA) may circumvent rHuEpo resistance, while oral AA is readily attainable. The aim of this study was to evaluate efficacy and safety of oral versus intravenous vitamin C in FID and whether this can improve anemia in hemodialy-sis patients. Materials and Methods: In this study, 31 hemo-dialysis patients with serum ferritin >100 µg/L, transferin saturation (Tsat) <30% and Hb<11g/dL were selected and randomly divided into the oral and IV groups. The IVAA group received vi-tamin C 1.5 g, administered weekly and the oral group, 125 mg vitamin C daily for two months. Hb, ferritin, serum iron, Tsat and serum oxalate were measured at the beginning of the study and 2 months later. Independent–sample T-Test were used for intergroup comparison. P value <0/05 was considered significant. Results: Mean Hb difference was 1.1±0.7 g/dL in the oral and 0.1±1 g/dL in the IVAA group, being significantly higher in the oral group (p=0.02). There were no significant differences between the two groups in the delta means of ferritin & Tsat (p=0.5, p=0.3). Delta means of serum oxalate in the 2 groups were 0.05±0.4 mg/L, and 0.1± 0.3 mg/L respectively, difference not significant (p=0.3). Conclusion: Oral AA significantly increased Hb in HD patients suffering from FID. Considering the feasibility and cost-effectiveness, clinicians could consider oral instead IVAA in rHuEpo hy-poresponsive patients undergoing HD.

Keywords

Anemia

Functional iron deficiency

Full Text

Full text is available in PDF

comments